Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer

Active surveillance has been proposed as a therapeutic option in selected intermediate risk patients with biopsy grade group 2 prostate cancer. However, its oncologic safety in this setting is debated. Therefore, we conducted a non-systematic literature research of contemporary surveillance protocol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandaglia, Giorgio, Leni, Riccardo, Plagakis, Sophie, Stabile, Armando, Montorsi, Francesco, Briganti, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542696/
https://www.ncbi.nlm.nih.gov/pubmed/37777767
http://dx.doi.org/10.1186/s12894-023-01315-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542696/
https://www.ncbi.nlm.nih.gov/pubmed/37777767
http://dx.doi.org/10.1186/s12894-023-01315-5

Ejemplares similares